Chronic Bronchitis News and Research

RSS

Study: Cigarette smoking linked to mucus overproduction in patients with chronic bronchitis

Cigarette smoking has been linked with overproduction of mucus associated with chronic bronchitis, according to a study conducted by researchers in New Mexico. The study indicates cigarette smoke suppresses a protein that causes the natural death of mucus-producing cells in the airways of bronchitis patients.

17 Feb 2011

Experts say signs and treatment of bacterial infection often misunderstood

According to the Canadian Foundation for Infectious Diseases, antibiotics are the second most frequently prescribed class of drugs - second only to pain relievers. Yet most people don't know the difference between a true bacterial infection, like chronic bronchitis that can be treated with antibiotics — and viruses like the common cold, which cannot.

17 Feb 2011

COPD becomes third leading cause of death in the U.S.

The Centers for Disease Control (CDC) and Prevention's National Center for Health Statistics (NCHS) released a report today, "Deaths: Preliminary Data for 2008," confirming that Chronic Obstructive Pulmonary Disease (COPD) became the third leading cause of death in the U.S. for 2008.

10 Dec 2010

Exposure to tobacco smoke causes immediate damage leading to serious illness or death

Exposure to tobacco smoke - even occasional smoking or secondhand smoke - causes immediate damage to your body that can lead to serious illness or death, according to a report released today by U.S. Surgeon General Regina M. Benjamin. The comprehensive scientific report - Benjamin's first Surgeon General's report and the 30th tobacco-related Surgeon General's report issued since 1964 - describes specific pathways by which tobacco smoke damages the human body and leads to disease and death.

10 Dec 2010

Dogs help understand primary ciliary dyskinesia

A dog is mankind's best friend : the old saying has once again been borne out through a medical discovery concerning the genetic origins of primary ciliary dyskinesia (PCD). In using dogs as a research model in the framework of the European LUPA project, a team from the University of Liège's GIGA-Research Unit has been able to bring to light new mutations in a specific gene responsible for the development of the disease in human beings.

9 Dec 2010

NHLBI launches new campaign to highlight common COPD symptoms

The number of Americans who report being aware of chronic obstructive pulmonary disease, or COPD, increased by 4 percentage points between 2008 and 2010, but many people at risk are still unaware of the disease, according to mailed survey results released today by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

10 Nov 2010

Taste receptors in lungs can revolutionize treatment option for asthma

Taste receptors in the lungs. Researchers at the University of Maryland School of Medicine in Baltimore have discovered that bitter taste receptors are not just located in the mouth but also in human lungs. What they learned about the role of the receptors could revolutionize the treatment of asthma and other obstructive lung diseases.

25 Oct 2010

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $1.00 in the second quarter of fiscal 2011.

19 Oct 2010

American Lung Association data shows improvement in health benefits

The American Lung Association in California released new data today showing significant public health benefits from pursuing a smart growth future for California. The American Lung Association data shows health benefits, including reduced asthma attacks and premature deaths linked to the Vision California "mixed growth" and "growing smart" scenarios in 2035 that include more compact, sustainable development patterns.

17 Sep 2010

Forest files response to FDA Complete Response Letter for roflumilast NDA

Forest Laboratories, Inc. today announced that it has filed a response to the U.S. Food & Drug Administration (FDA) addressing topics raised in the complete response letter regarding the New Drug Application (NDA) for roflumilast. Forest licenses roflumilast from Nycomed, which submitted the original NDA.

13 Sep 2010

Research finds immune system mechanism to minimize collateral damage

A study published today in the journal Science shows how our bodies try to minimise potential 'collateral damage' caused by our immune system when fighting infection. The research may also provide new clues to why cigarette smoke is a significant risk factor for developing diseases of the lung such as chronic bronchitis and emphysema.

3 Sep 2010

Second-hand smoke triggers complex inflammatory response

Second-hand smoke is associated with a number of diseases and conditions, including cancer, heart disease, and emphysema. It is an irritant to lung tissue and blood vessels, but the processes through which the body reacts to second-hand smoke comprise a mystery scientists are only beginning to unravel. Researchers at the University of Colorado-Denver are currently studying how second-hand smoke affects the lungs of rats, and so far it appears that second-hand smoke triggers a complex inflammatory response.

27 Aug 2010

Tips for management of COPD

What is the fourth leading cause of death in the United States? Many would be surprised to learn that chronic obstructive pulmonary disease (COPD) is, and the number of people with COPD is increasing. According to the COPD Foundation, more than 12 million Americans are currently diagnosed with COPD and an additional 12 million may not realize their shortness of breath and coughing are in fact symptoms of this debilitating condition.

20 Aug 2010

Forest Laboratories reports first-quarter diluted EPS of $0.39

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.39 in the first quarter of fiscal 2011. Excluding the charge related to the United States Department of Justice investigations described below, and a charge of $50.0 million, or $0.17 per share net of tax, for a new product licensing fee, non-GAAP earnings per share for the first fiscal quarter were $0.95 per share.

20 Jul 2010

Chronic insomnia increases mortality risk

Individuals with chronic insomnia have an elevated risk of death, according to a research abstract that will be presented Monday, June 7, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

7 Jun 2010

Beta-blocker medications provide new hope for patients with COPD: Study

Patients with chronic obstructive pulmonary disease may have fewer respiratory flare-ups and longer survival if they take beta-blocker medications, according to a report in the May 24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

25 May 2010

FDA issues complete response letter for roflumilast NDA

Forest Laboratories, Inc. and Nycomed today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for roflumilast. Roflumilast was reviewed as a potential treatment to reduce COPD exacerbations associated with chronic bronchitis in patients at risk for exacerbations.

18 May 2010

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Forest Laboratories, Inc. and Nycomed today announced that they will present data from six roflumilast posters during the American Thoracic Society (ATS) International Conference being held in New Orleans, LA, May 14 through May 19, 2010. Roflumilast is an investigational anti-inflammatory, oral medication for the treatment of Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis in patients at risk of exacerbations.

10 May 2010

Natural plant extract could help treat COPD and inflammatory disorders

A widely and safely used plant extract acts as a novel anti-inflammatory agent that may one day be used for the treatment of chronic obstructive pulmonary disease, or COPD, as well as other inflammatory conditions.

4 May 2010

70% of COPD patients under-diagnosed due to lack of disease knowledge

"It is high time to demystify COPD in order to better explain the issues and help people who suffer from this disease," says Dr. Jean Bourbeau, Director of the Respiratory, Epidemiology and Clinical Research Unit at the Montreal Chest Institute of the MUHC, and lead investigator of CanCOLD along with Dr. Wan Tan of The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, University of British Columbia.

17 Apr 2010